Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database

References

• French National Cancer Institute. Cancer INd. Les Cancers en France. Institut National du Cancer, 2015
   Google Scholar
• Larkin J, Paine A, Tumur I, et al. Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 2013;14:27-39
   PubMed Web of Science ®Google Scholar
• Hansen RN, Hackshaw MD, Nagar SP, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm 2015;21:37-44, 44a-d
   PubMed Web of Science ®Google Scholar
• Pal SK, Nelson RA, Vogelzang N. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One 2013;8:e63341
   PubMed Web of Science ®Google Scholar
• Argyropulo-Palmer M, Jenkins A, Theti DS, et al. Sunitinib in metastatic renal cell carcinoma: a systematic review of UK real world data. Front Oncol 2015;5:195
   PubMed Web of Science ®Google Scholar
• Harrison MR, George DJ, Walker MS, et al. “Real world” treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. Clin Genitourin Cancer 2013;11:441-50
   PubMed Web of Science ®Google Scholar
• Harrison MR, Hirsch BR, George DJ, et al. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community–Academic Registry. J Oncol Pract 2014;10:e63-72
   PubMedGoogle Scholar
• Choueiri TK, Duh MS, Clement J, et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 2010;105:1247-54
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer 2015;13:e93-100
   PubMedGoogle Scholar
• Day D, Kanjanapan Y, Kwan E, et al. Patterns of care for metastatic renal cell carcinoma in Australia. BJU Int 2015;116(Suppl 3):36-41
   PubMed Web of Science ®Google Scholar
• Jonasch E, Signorovitch JE, Lin PL, et al. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Curr Med Res Opin 2014;30:2041-50
   PubMed Web of Science ®Google Scholar
• Duh MS, Dial E, Choueiri TK, et al. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin 2009;25:2081-90
   PubMed Web of Science ®Google Scholar
• Choueiri TK, McDermott D, Sheng Duh M, et al. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. Urol Oncol 2012;30:848-55
   PubMed Web of Science ®Google Scholar
• MacLean E, Mardekian J, Cisar LA, et al. Real-world treatment patterns and costs for patients with renal cell carcinoma initiating treatment with sunitinib and pazopanib. J Manag Care Spec Pharm 2016;22:979-90
   PubMed Web of Science ®Google Scholar
• Maroun R, Maunoury F, Benjamin L, et al. In-hospital economic burden of metastatic renal cell carcinoma in France in the era of targeted therapies: analysis of the French national hospital database from 2008 to 2013. PLoS One 2016;11:e0162864
   PubMed Web of Science ®Google Scholar
• Noize P, Grelaud A, Bay JO, et al. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. Pharmacoepidemiol Drug Saf 2017: published online 1 June 2017. doi: 10.1002/pds.4228
   Google Scholar
• Joly F, Eymard JC, Albiges L, et al. A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France. Support Care Cancer 2017;25:2055-62
   PubMed Web of Science ®Google Scholar
• Matias M, Le Teuff G, Albiges L, et al. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. Eur J Cancer 2017;79:185-92
   PubMed Web of Science ®Google Scholar
• Moulis G, Lapeyre-Mestre M, Palmaro A, et al. French health insurance databases: what interest for medical research? Rev Med Interne 2015;36:411-17
   PubMed Web of Science ®Google Scholar
• Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010;58:286-90
   PubMed Web of Science ®Google Scholar
• Tuppin P, Samson S, Fagot-Campagna A, Woimant F. Care pathways and healthcare use of stroke survivors six months after admission to an acute-care hospital in France in 2012. Rev Neurol (Paris) 2016;172:295-306
   PubMed Web of Science ®Google Scholar
• Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
   PubMed Web of Science ®Google Scholar
• Meyer N, Hao Y, Song X, et al. Healthcare resource use and expenditures among metastatic breast cancer patients treated with HER2-targeted agents. Int J Breast Cancer 2014;2014:475171
   PubMedGoogle Scholar
• OECD. Consumer Price Index. Available at: https://stats.oecd.org/Index.aspx?lang=en&SubSessionId=8c6ba40f-722c-41f2-9851-b12f7de3e216&themetreeid =16# [Last accessed 17 June 2017]
   Google Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-24
   PubMed Web of Science ®Google Scholar
• Wagstaff J, Jones R, Hawkins R, et al. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol 2016;27:159-65
   PubMed Web of Science ®Google Scholar